vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and Sunlands Technology Group (STG). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $10.1M, roughly 1.5× Sunlands Technology Group). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs 0.6%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.

IRIX vs STG — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.5× larger
IRIX
$14.7M
$10.1M
STG
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
0.6%
STG

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IRIX
IRIX
STG
STG
Revenue
$14.7M
$10.1M
Net Profit
$2.4M
Gross Margin
37.2%
88.5%
Operating Margin
26.5%
Net Margin
24.0%
Revenue YoY
-69.7%
Net Profit YoY
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
STG
STG
Q4 25
$14.7M
Q3 25
$12.5M
$10.1M
Q2 25
$13.6M
$9.3M
Q1 25
$11.9M
Q4 24
$12.7M
$9.7M
Q3 24
$11.6M
Q2 24
$12.6M
$10.0M
Q1 24
$11.8M
Net Profit
IRIX
IRIX
STG
STG
Q4 25
Q3 25
$-1.6M
$2.4M
Q2 25
$-994.0K
$1.4M
Q1 25
$-1.7M
Q4 24
$-834.0K
$1.8M
Q3 24
$-1.9M
Q2 24
$-2.7M
$2.2M
Q1 24
$-3.5M
Gross Margin
IRIX
IRIX
STG
STG
Q4 25
37.2%
Q3 25
32.1%
88.5%
Q2 25
34.5%
85.2%
Q1 25
42.5%
Q4 24
44.0%
83.3%
Q3 24
37.3%
Q2 24
40.7%
85.2%
Q1 24
37.9%
Operating Margin
IRIX
IRIX
STG
STG
Q4 25
Q3 25
-11.3%
26.5%
Q2 25
-6.9%
15.2%
Q1 25
-1.7%
Q4 24
-3.9%
13.4%
Q3 24
-16.1%
Q2 24
-20.9%
Q1 24
-28.0%
Net Margin
IRIX
IRIX
STG
STG
Q4 25
Q3 25
-12.6%
24.0%
Q2 25
-7.3%
15.4%
Q1 25
-14.2%
Q4 24
-6.6%
18.2%
Q3 24
-16.7%
Q2 24
-21.2%
21.5%
Q1 24
-29.5%
EPS (diluted)
IRIX
IRIX
STG
STG
Q4 25
Q3 25
$-0.09
Q2 25
$-0.06
Q1 25
$-0.10
Q4 24
$-0.05
Q3 24
$-0.12
Q2 24
$-0.16
$0.31
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
STG
STG
Cash + ST InvestmentsLiquidity on hand
$6.0M
$15.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$17.7M
Total Assets
$29.2M
$41.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
STG
STG
Q4 25
$6.0M
Q3 25
$5.6M
$15.1M
Q2 25
$6.8M
Q1 25
$7.2M
Q4 24
$2.4M
$15.6M
Q3 24
$3.9M
Q2 24
$4.1M
$18.7M
Q1 24
$5.4M
Total Debt
IRIX
IRIX
STG
STG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$1.0M
$1.5M
Q3 24
$1.4M
Q2 24
$1.8M
Q1 24
Stockholders' Equity
IRIX
IRIX
STG
STG
Q4 25
Q3 25
$4.7M
$17.7M
Q2 25
$6.1M
$12.6M
Q1 25
$852.0K
Q4 24
$2.1M
$10.7M
Q3 24
$2.6M
Q2 24
$4.2M
$7.6M
Q1 24
$6.5M
Total Assets
IRIX
IRIX
STG
STG
Q4 25
$29.2M
Q3 25
$28.4M
$41.2M
Q2 25
$31.6M
$40.3M
Q1 25
$34.2M
Q4 24
$29.1M
$42.4M
Q3 24
$30.2M
Q2 24
$31.2M
$41.3M
Q1 24
$34.1M
Debt / Equity
IRIX
IRIX
STG
STG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.48×
0.14×
Q3 24
0.53×
Q2 24
0.24×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons